Compare PACB & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACB | CGC |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.8M | 467.3M |
| IPO Year | 2010 | 2023 |
| Metric | PACB | CGC |
|---|---|---|
| Price | $1.35 | $1.06 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $1.67 | N/A |
| AVG Volume (30 Days) | ★ 7.0M | 3.5M |
| Earning Date | 05-07-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 84.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $93,468,000.00 | $12,759,000.00 |
| Revenue This Year | $11.32 | $8.27 |
| Revenue Next Year | $12.14 | $15.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.04 | N/A |
| 52 Week Low | $1.07 | $0.84 |
| 52 Week High | $2.73 | $2.38 |
| Indicator | PACB | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 65.70 |
| Support Level | $1.27 | $1.01 |
| Resistance Level | $1.47 | $1.08 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 66.25 | 90.91 |
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.